Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study

被引:80
作者
Fardet, Laurence [1 ,2 ,3 ,4 ]
Petersen, Irene [4 ]
Nazareth, Irwin [1 ,4 ]
机构
[1] UCL, Sch Med, MRC Gen Practice Res Framework, London W1N 8AA, England
[2] Hosp St Antoine, AP HP, Serv Med Interne, Paris, France
[3] Univ Paris 06, UPMC Paris 6, Fac Med, Paris, France
[4] UCL, Sch Med, Res Dept Primary Care & Populat Hlth, London W1N 8AA, England
来源
BMJ-BRITISH MEDICAL JOURNAL | 2012年 / 345卷
关键词
CORTICOSTEROID-INDUCED LIPODYSTROPHY; ACQUIRED GENERALIZED LIPODYSTROPHY; ORAL CORTICOSTEROIDS; ADVERSE EVENTS; DISEASE; VALIDATION; DATABASE; MORTALITY; DIAGNOSES; FEATURES;
D O I
10.1136/bmj.e4928
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To investigate whether there is an increased risk of cardiovascular events in people who exhibit iatrogenic Cushing's syndrome during treatment with glucocorticoids. Design Cohort study. Setting 424 UK general practices contributing to The Health Improvement Network database. Participants People prescribed systemic glucocorticoids and with a diagnosis of iatrogenic Cushing's syndrome (n=547) and two comparison groups: those prescribed glucocorticoids and with no diagnosis of iatrogenic Cushing's syndrome (n=3231) and those not prescribed systemic glucocorticoids (n=3282). Main outcome measures Incidence of cardiovascular events within a year after diagnosis of iatrogenic Cushing's syndrome or after a randomly selected date, and association between iatrogenic Cushing's syndrome and risk of cardiovascular events. Results 417 cardiovascular events occurred in 341 patients. Taking into account only the first event by patient (coronary heart disease n=177, heart failure n=101, ischaemic stroke n=63), the incidence rates of cardiovascular events per 100 person years at risk were 15.1 (95% confidence interval 11.8 to 18.4) in those prescribed glucocorticoids and with a diagnosis of iatrogenic Cushing's syndrome, 6.4 (5.5 to 7.3) in those prescribed glucocorticoids without a diagnosis of iatrogenic Cushing's syndrome, and 4.1 (3.4 to 4.8) in those not prescribed glucocorticoids. In multivariate analyses adjusted for sex, age, intensity of glucocorticoid use, underlying disease, smoking status, and use of aspirin, diabetes drugs, antihypertensive drugs, lipid lowering drugs, or oral anticoagulant drugs, the relation between iatrogenic Cushing's syndrome and cardiovascular events was strong (adjusted hazard ratios 2.27 (95% confidence interval 1.48 to 3.47) for coronary heart disease, 3.77 (2.41 to 5.90) for heart failure, and 2.23 (0.96 to 5.17) for ischaemic cerebrovascular events). The adjusted hazard ratio for any cardiovascular event was 4.16 (2.98 to 5.82) when the group prescribed glucocorticoids and with iatrogenic Cushing's syndrome was compared with the group not prescribed glucocorticoids. Conclusion People who use glucocorticoids and exhibit iatrogenic Cushing's syndrome should be aggressively targeted for early screening and management of cardiovascular risk factors.
引用
收藏
页数:13
相关论文
共 39 条
[1]   Impact of glucocorticoid-induced adverse events on adherence in patients receiving long-term systemic glucocorticoid therapy [J].
Arena, C. ;
Morin, A. -S. ;
Blanchon, T. ;
Hanslik, T. ;
Cabane, J. ;
Dupuy, A. ;
Fardet, L. .
BRITISH JOURNAL OF DERMATOLOGY, 2010, 163 (04) :832-837
[2]  
Bourke Alison, 2004, Inform Prim Care, V12, P171
[3]   Does central obesity reflect ''Cushing's disease of the omentum''? [J].
Bujalska, IJ ;
Kumar, S ;
Stewart, PM .
LANCET, 1997, 349 (9060) :1210-1213
[4]   Diseases of adipose tissue:: genetic and acquired lipodystrophies [J].
Capeau, J ;
Magré, J ;
Lascols, O ;
Caron, M ;
Béréziat, V ;
Vigouroux, C ;
Bastard, JP .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2005, 33 :1073-1077
[5]  
Capeau J, 2010, ENDOCR DEV, V19, P1, DOI 10.1159/000316893
[6]   THE READ CLINICAL CLASSIFICATION [J].
CHISHOLM, J .
BRITISH MEDICAL JOURNAL, 1990, 300 (6732) :1092-1092
[7]   Creating medical and drug code lists to identify cases in primary care databases [J].
Dave, Shreya ;
Petersen, Irene .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 (08) :704-707
[8]   Increased Risk of Myocardial Infarction and Stroke Following Exacerbation of COPD [J].
Donaldson, Gavin C. ;
Hurst, John R. ;
Smith, Christopher J. ;
Hubbard, Richard B. ;
Wedzicha, Jadwiga A. .
CHEST, 2010, 137 (05) :1091-1097
[9]   Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome [J].
Fardet, L. ;
Cabane, J. ;
Kettaneh, A. ;
Lebbe, C. ;
Flahault, A. .
RHEUMATOLOGY, 2007, 46 (07) :1102-1106
[10]   Corticosteroid-induced clinical adverse events:: frequency, risk factors and patient's opinion [J].
Fardet, L. ;
Flahault, A. ;
Kettaneh, A. ;
Tiev, K. P. ;
Genereau, T. ;
Toledano, C. ;
Lebbe, C. ;
Cabane, J. .
BRITISH JOURNAL OF DERMATOLOGY, 2007, 157 (01) :142-148